Dietary short chain fatty acids protect against type 1 diabetes by Wen, L & Wong, FS
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/100313/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Wen, L and Wong, FS 2017. Dietary short chain fatty acids protect against type 1 diabetes. Nature
Immunology 18 (5) , pp. 484-486. 10.1038/ni.3730 file 
Publishers page: http:dx.doi.org/10.1038/ni.3730 <http:dx.doi.org/10.1038/ni.3730>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Dietary short chain fatty acids protect against type 1 diabetes 
	
	
	
	
Li Wen 
1 
& F. Susan Wong 
2
 
	
	
1
Section of Endocrinology, Department of Internal Medicine, Yale University School of 
	
Medicine, New Haven, Connecticut 06520, USA 
	
	
	
2
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 
	
4XN, UK 
	
	
	
Correspondence to Li Wen: li.wen@yale.edu 
	
	
	
	
	
	
	
	
	
	
Dr. Wen is supported by NIH (DK092882, DK100500, P30DK045735), JDRF (1-INO-
2015-136) and ADA (1-14-BS-222).  Dr. Wong is supported by UK Medical Research 
Council (MR/K021141/1), Diabetes UK, European Foundation for the Study of Diabetes, 
JDRF and the British Council. 
	Short chain fatty acids (SCFAs), acetate and butyrate, which are released by 
specialized diets by gut microbiobes, protect non-obese diabetic (NOD) mice against 
insulitis and slow the progression of diabetes.  
 
Increasing evidence emphasizes the important role of gut microbiota in type 1 diabetes 
development.  It is clear that the composition of gut microbiota changes prior to and after 
diabetes onset; however, it is not clear how these change in gut microbiota affect the disease 
development.  Some of these effects may relate to the metabolites produced by the 
microbiota.  
Using the Non Obese Diabetic (NOD) mouse that develops spontaneous diabetes with 
considerable similarities to human type 1 diabetes, Marino and colleagues report a 
comprehensive study on the importance of the microbial metabolites acetate and butyrate, 
which are short-chain fatty acids (SCFAs), in autoimmune diabetes
1
. They build on the 
knowledge that the progression of diabetes correlates inversely with blood and fecal 
concentrations of these SCFAs, designing diets to release acetate and butyrate. Their data 
show that these diets boost the c o n c e n t r a t i o n s  of acetate or butyrate respectively, in 
the feces, hepatic and peripheral blood. The mice on both diets exhibit a significant 
reduction of insulitis and diabetes development, accompanied by an increase in gut 
integrity, with a marked synergy in diabetes protection when a combined diet is used. 
	
Interestingly, the SCFA- rich diets have a strong impact on the immune system through 
different modes of action. Whereas the acetate diet reduces splenic B cells, especially 
transitional and marginal zone (MZ) B cells, which are required for autoreactive T cell 
prol i fera t ion, the butyrate diet increases regulatory T cell number and function 
(Fig.1). Marino and colleagues further test the immune regulatory effect of SCFA-rich 
diets in the T cell antigen receptor (TCR) transgenic NY8.3 NOD mouse, which is an 
accelerated diabetes model. NY8.3 TCR recognizes an islet protein peptide, islet-specific 
glucose-6- phosphatase catalytic subunit-related protein (IGRP). In these NY8.3 mice, the 
majority of the T cells are diabetogenic CD8
+
 T cells and often 100% of these mice 
develop diabetes by about 12 weeks of age. Impressively, the butyrate and acetate rich diets 
delayed diabetes development by 19 and 25 weeks, respectively. The authors find that the 
acetate-rich diet considerably reduces IGRP-reactive CD8 T cells in the periphery, possibly 
by inhibiting the proliferation of NY8.3 CD8
+
 T cells. However, since the suppression is 
surprisingly strong, it would be interesting to learn whether acetate has any effect on the 
generation of these NY8.3 CD8
+
 T cells in the thymus. 
	
NOD mice deficient in the signaling adaptor protein MyD88, which governs innate 
immunity, are completely protected from diabetes development. The diabetes protection, in 
this model, is mediated by altered gut microbiota
2
. However, removing commensal bacteria 
from MyD88-deficient NOD mice by re-deriving them into a germ-free environment 
abolishes the disease protection
2
. Marino and colleagues find that diabetes protection in 
MyD88-deficient NOD mice housed in specific pathogen-free conditions is associated with 
high concentrations of SCFAs in the circulation
1
. It is worth mentioning that this 
observation occurs are on a conventional diet. This result is was also observed in wild-type 
NOD mice, in which diabetes development is negatively correlated with the concentration 
of SCFAs contributed by the gut microbiota. Taken together, these findings are exciting in 
indicating the potential to develop a natural therapy that could be used to correct 
immunological defects that may contribute to disease. 
	
Type 1 diabetes and other autoimmune diseases have polygenic determinants of 
susceptibility. However, it is clear that the disease onset requires other factors either to 
initiate or perpetuate the autoimmune process. Studies in identical twins in type 1 diabetes 
have provided strong evidence for these other factors, as the diabetes concordance rate is 
less than 50%
3
. While we have learned that environmental factors may interact with 
genetics and lead to disease onset, there is no clear consensus as to the environmental 
causes. The gut is an obvious interface with the environment. Indeed, the gut mucosal 
immune system is vital for the maturation of immune system and the generation of 
immune tolerance to food and other foreign antigens, via the oral-gastrointestinal route. 
Research on the microbiota in health and disease has significantly expanded in recent 
years, including the investigation of the contribution of the microbiota to the pathogenesis 
of type 1 diabetes. Studies in both diabetic NOD mice and humans suggest differences in 
the gut microbiota between those that develop diabetes, as compared with those who do 
not. Such differences include a reduction of diversity in the composition of gut microbiota 
and this reduction is more evident before the time of diabetes onset
4
. A recent study 
reported that Russian children, who have a low incidence of type 1 diabetes, have a low 
abundance of Bacteroides species compared with a high abundance of these bacteria in 
children from Finland and Estonia, where the incidence of type 1 diabetes is also much 
higher
5
. 
	
	Treatment and prevention of this complex autoimmune disease, other than replacement of 
insulin, has been elusive. A number of strategies for immunotherapy as treatment for type 
1 diabetes have now been trialed in individuals who have already developed diabetes, 
and these include non-antigen-specific therapies that target T or B cells
6
. All of these 
require intravenous administration and have shown some efficacy in the short term, but for 
a number of reasons, are not yet viable current treatment options. Antigen-specific therapy 
has also been attempted, but this approach is still in its infancy6. It would be of 
considerable importance to identify a treatment modality that could be given safely and 
easily administered, which had a local effect and that could potentially be repeated. 
Additionally, the possibility of primary prevention of type 1 diabetes with a diet-based 
treatment would be of considerable interest
7
. 
	
	
The beneficial effects of SCFAs have been known for some time. A number of 
inflammatory diseases including allergic airways disease
8
, and type 2 diabetes
9 
can be 
improved in mouse models by boosting SCFAs.  On the other hand, it will be important to 
ensure that, in reducing inflammation and boosting regulation, treatments do not increase 
the risk of cancers as a side effect; for example, acetate has been shown to be a good 
substrate for glucose-starved tumors in vitro and in an animal model
10
.		
	
Most of the studies showing an immune regulatory effect of SCFAs have concentrated on 
the induction of r e g u l a t o r y  T cells
11
.   It is very interesting that Marino and 
colleagues find that SCFA-enriched diets also have a clear effect on B cells, especially 
marginal zone (MZ) B cells, which are markedly reduced in number and function.  It is not 
clear whether SCFAs have any effect on plasma cells, as MZ B cells can become long-
lived plasma cells that secrete both T-dependent and independent antibodies
12,13
.   It would 
be interesting to know if SCFAs affect mucosal IgA- producing B cells. 
	
	
Given the current information on the diversity of the gut microbiota, it is unlikely that we 
will find one therapeutic combination of bacteria for type 1 diabetes that will be 
universally beneficial. The evidence so far suggests that groups of bacteria have more or 
less beneficial effects in diabetes and other diseases, and these findings extend the 
importance of bacteria that produce these SCFA metabolites. What is particularly 
important here is that these findings, and the observations of others, suggest that 
understanding which bacteria produce specific classes of metabolites may be more 
informative than the individual bacteria themselves. By the same token, identifying the 
bacterial products that promote diabetes development is also crucial
5,14 
as not all gut 
microbiota are beneficial for the health of the host. However, boosting beneficial bacterial 
metabolites, including SCFAs, by incorporating them into the diet would be a very attractive 
strategy. The different but synergistic effects that individual SCFAs have on the immune 
system would allow for an improved outcome. These beneficial effects, which include 
reduction in pathogenic cells and an increase in regulatory type cells would be of particular 
importance, not only for autoimmune diabetes, but potentially other autoimmune diseases, 
which may occur in part because of deficient function in regulatory cells. However, a 
cautionary note should be added, as although most of the studies suggest that SCFAs 
promote immunoregulation and ameliorate autoimmune diseases, SCFAs can also 
exacerbate some autoimmune disorders
15
. Thus, more work is required to understand the 
further effects of these short chain fatty acids as provided by diets, both beneficial and 
potentially deleterious in a human context. 
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Fig.1. Specialized diets protect against type 1 diabetes.  
Diet can affect the composition of gut microbiota and the gut microbiota affect metabolites that can be 
derived from the diet.  High-amylose maize is high-fiber starch and promotes the generation of short 
chain fatty acids (SCFAs) by gut microbiota in the process of fermentation.  Acetate and butyrate are 
major SCFAs.  Diets with acetylated or butyrylated high-amylose maize starch further increase the 
concentrations of SCFAs in the body of the host.  Acetate reduces marginal zone B (MZB) cells, 
which facilitate the proliferation of islet-autoantigen-reactive T cells, whereas butyrate increases the 
number and function of regulatory T (Treg) cell.   Both of these effects reduce insulitis and diabetes in 
NOD mice.  Hematoxylin and eosin histopathology images (right) from Marino et al1. 
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